Form 8-K - Current report:
SEC Accession No. 0000950170-22-021867
Filing Date
2022-11-03
Accepted
2022-11-03 16:10:42
Documents
13
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtyx-20221103.htm   iXBRL 8-K 58925
2 EX-99.1 vtyx-ex99_1.htm EX-99.1 232757
  Complete submission text file 0000950170-22-021867.txt   427469

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtyx-20221103_lab.xml EX-101.LAB 14572
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtyx-20221103_pre.xml EX-101.PRE 10671
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtyx-20221103.xsd EX-101.SCH 2460
7 EXTRACTED XBRL INSTANCE DOCUMENT vtyx-20221103_htm.xml XML 5117
Mailing Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024
Business Address 662 ENCINITAS BLVD., STE. 250 ENCINITAS CA 92024 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

EIN.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40928 | Film No.: 221358082
SIC: 2834 Pharmaceutical Preparations